Brochure | September 5, 2014

Immunogenicity Assessment Services Improve Safety, Efficacy And Cost Of Development

The safety and efficacy of biological candidates are critical to their clini­cal success. The proteinaceous nature of many drug candidates can lead to an immunogenic response in the patient. The proteins may aggregate or have epitopes that are recognized by the immune system. Once the immune system is activated, the efficacy of the biotherapeutic declines as the system attempts to clear the antigen. The immune response itself affects product safety as cytokine release can be toxic to the patient. For biotherapeutic development, avoiding this response is vital for success.

Alternatively, for vaccine development, triggering an immune response is desired. Designing and assessing vaccine candidates for the appropriate immune response is critical for their success.

Animal testing is used in an effort to assess the potential immunogenic­ity of biotherapeutic and vaccine candidates. The response in animals can be helpful to researchers; however, it is often not a good indicator of what the human immune response will be to the biological candidate.

VIEW THE BROCHURE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: